Welcome to our dedicated page for Climb Bio SEC filings (Ticker: CLYM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Climb Bio, Inc. (Nasdaq: CLYM) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Climb Bio is a clinical-stage biotechnology company developing monoclonal antibody therapeutics for immune-mediated and B-cell mediated diseases, and its filings offer structured insight into how it reports material events, governance changes, and financial updates.
Recent Form 8-K filings describe key developments such as quarterly financial results, publication of clinical data for budoprutug in primary membranous nephropathy, and new preclinical data for CLYM116 in IgA nephropathy. Other 8-Ks detail the appointment of senior executives, including the Chief Financial Officer, and related equity awards granted under the company’s 2025 Inducement Plan, as well as amendments to increase the share reserve under that plan. These documents also confirm that Climb Bio’s common stock trades on The Nasdaq Global Market under the symbol CLYM.
Through Stock Titan, users can review Climb Bio’s SEC filings alongside AI-powered summaries that highlight the main points of each document. This includes explanations of how the company characterizes the therapeutic potential and clinical development of budoprutug and CLYM116 in its disclosures, and how it describes risks and forward-looking statements associated with its programs. The filings page is also a resource for tracking regulatory communications around investor events, data releases, and other reportable events.
By using this page, investors and researchers can quickly locate Climb Bio’s 8-Ks and other SEC reports and rely on AI-generated overviews to understand the significance of each filing without reading every line of the underlying documents.
Climb Bio, Inc. is a clinical-stage biotechnology company focused on immune-mediated diseases. Its lead antibody, budoprutug, targets CD19 to deplete pathogenic B cells in primary membranous nephropathy (pMN), immune thrombocytopenia (ITP) and systemic lupus erythematosus (SLE). Budoprutug has orphan-drug designation for pMN, encouraging Phase 1b data in pMN, and multiple ongoing Phase 1/2 trials in pMN, ITP and SLE, including an intravenous and a high‑concentration subcutaneous formulation.
The company’s second program, CLYM116, is a next-generation anti‑APRIL ‘sweeper’ antibody aimed at IgA nephropathy and other B‑cell–mediated diseases. Early preclinical work suggests deep and durable APRIL and IgA suppression, and Phase 1 trials in healthy volunteers and parallel studies with partner Mabworks in China are underway. Climb Bio estimates its targeted indications encompass more than 500,000 U.S. patients, with broader potential across roughly 2 million people living with immune‑mediated diseases.
Climb Bio, Inc. reported fourth quarter and full-year 2025 results showing continued investment in its immune-mediated disease pipeline and a stronger balance sheet. Cash, cash equivalents and marketable securities were $160.7 million as of December 31, 2025, which the company expects will fund operations into 2028.
Full-year 2025 research and development expenses rose to $46.7 million from $14.3 million, while general and administrative expenses increased to $21.2 million from $16.0 million, reflecting pipeline and corporate growth. Net loss narrowed to $59.9 million in 2025 from $73.9 million in 2024, with loss per share improving to $0.88 from $1.53.
The company highlighted progress in multiple clinical programs. Budoprutug is in ongoing trials for primary membranous nephropathy, immune thrombocytopenia and systemic lupus erythematosus, plus a completed Phase 1 study of a subcutaneous formulation, with initial data from several studies expected in 2026. CLYM116 is in a Phase 1 healthy volunteer study, supported by a partner-led Phase 1/2 trial in IgA nephropathy.
Climb Bio, Inc. director Thomas Stephen Basil reported selling a total of 50,000 shares of Common Stock in open-market transactions under a pre-arranged Rule 10b5-1 trading plan. On
Form 144 filing reporting a proposed sale of
BioImpact LLC filed a Schedule 13G reporting a significant passive stake in Climb Bio, Inc.. BioImpact beneficially owns 2,671,480 shares of Climb Bio common stock, representing 5.6% of the class as of 12/31/2025.
BioImpact has sole power to vote and dispose of all reported shares, with no shared voting or dispositive power. The filing states the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Climb Bio.
Climb Bio, Inc. director Thomas Stephen Basil reported selling a total of 100,000 shares of common stock in open-market transactions on February 12 and 13, 2026. He sold 90,000 shares at a weighted average price of $5.2332 on February 12 and 10,000 shares at a weighted average price of $5.8141 on February 13.
After these sales, Basil directly beneficially owns 204,657 shares of Climb Bio common stock. The filing states the trades were made under a Rule 10b5-1 trading plan adopted on October 14, 2025, and notes that each reported price reflects a weighted average of multiple individual trades within the disclosed price ranges.
The holder of CLYM common stock has filed a notice of proposed sale of 100,000 shares through Morgan Stanley Smith Barney on or after February 12, 2026 on NASDAQ, with an aggregate market value of $556,000. The filing states that 68,184,435 shares of this class were outstanding at the time of the notice.
The shares to be sold were acquired from the issuer as restricted stock units on January 1, 2025 (50,188 shares) and as founders’ shares on November 15, 2023 (49,812 shares). The seller represents that they are not aware of any undisclosed material adverse information about the issuer’s current or prospective operations.
Climb Bio, Inc. reported an equity award to its President and CEO, Brennan Aoife, who also serves as a director. On January 6, 2026, Aoife received a stock option to buy 700,000 shares of Climb Bio common stock at an exercise price of $3.81 per share. The filing shows this option is held directly and represents 700,000 derivative securities beneficially owned after the grant.
The option was granted as a long-term incentive. According to the vesting terms, 25% of the underlying shares vest on the first anniversary of the grant date, and the remaining shares vest in 36 equal monthly installments through January 6, 2030, as long as Aoife continues to serve the company. The option has an expiration date of January 5, 2036, giving a long window in which it can be exercised if vested.
Climb Bio, Inc. (CLYM) reported a stock option grant to Chief Business Officer Megan Wilson Perrin on a Form 4. On January 6, 2026, she received a stock option to buy 300,000 shares of common stock at an exercise price of $3.81 per share, expiring on January 5, 2036.
According to the vesting terms, 25% of the option shares vest on the first anniversary of the grant date, with the remaining shares vesting in 36 equal monthly installments through January 6, 2030, conditioned on her continued service with the company.
Climb Bio, Inc. reported that its Chief Financial Officer, Susan Altschuller, received a new stock option grant. On January 6, 2026, she was awarded a stock option to buy 142,500 shares of Climb Bio common stock at an exercise price of $3.81 per share. Following this grant, she beneficially owned 142,500 derivative securities in the form of this option, held directly.
The option vests over time. According to the disclosure, 25% of the shares vest on the first anniversary of the January 6, 2026 grant date, and the remaining shares vest in 36 equal monthly installments through January 6, 2030, as long as she continues in service. The option expires on January 5, 2036.